Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamara Everington

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
The Practitioner|February 13, 2007
Acquired mutation the key to MPDsTamara Everington
The Health Service Journal|June 3, 2005
Childcare. Back to the futureTamara Everington
Cardiology and Therapy|July 27, 2016
Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial FibrillationSufyan Benamer, Debbie Lusty, Tamara Everington
British Journal of Haematology|November 9, 2018
Updated 2018 NICE guidance on venous thromboembolism - does evidence from root cause analysis of hospital-associated thrombosis support the additional investment required?Nicola McQuaid, Peter Davies, Tamara Everington
Journal of Evaluation in Clinical Practice|October 12, 2021
"I just didn't want to trust it at all": Atrial fibrillation patient's treatment experience of rivaroxaban and warfarinDan Sly, Margaret Husted, Lynn McKeague, et al.
Clinical Medicine (London, England)|May 17, 2019
Venous thromboembolismSusan Shapiro, Tamara Everington, Lara Roberts, et al.
British Journal of Haematology|September 8, 2006
Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cellsVictoria L Grandage, Tamara Everington, David C Linch, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|April 20, 2004
-455G/A beta-fibrinogen gene polymorphism, factor V Leiden, prothrombin G20210A mutation and MTHFR C677T, and placental vascular complicationsRaymond S Camilleri, Donald Peebles, Carol Portmann, et al.
The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland|December 6, 2019
Mechanical prophylaxis, early mobilisation and risk stratification: as effective as drugs for low risk patients undergoing primary joint replacement. Results in 13,384 patientsSukhdeep K Gill, Andrea R Pearce, Tamara Everington, et al.
Blood|June 23, 2009
In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigmJonathan R Lambert, Tamara Everington, David C Linch, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
The Practitioner|February 13, 2007
Acquired mutation the key to MPDsTamara Everington
The Health Service Journal|June 3, 2005
Childcare. Back to the futureTamara Everington
Cardiology and Therapy|July 27, 2016
Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial FibrillationSufyan Benamer, Debbie Lusty, Tamara Everington
British Journal of Haematology|November 9, 2018
Updated 2018 NICE guidance on venous thromboembolism - does evidence from root cause analysis of hospital-associated thrombosis support the additional investment required?Nicola McQuaid, Peter Davies, Tamara Everington
Journal of Evaluation in Clinical Practice|October 12, 2021
"I just didn't want to trust it at all": Atrial fibrillation patient's treatment experience of rivaroxaban and warfarinDan Sly, Margaret Husted, Lynn McKeague, et al.
Clinical Medicine (London, England)|May 17, 2019
Venous thromboembolismSusan Shapiro, Tamara Everington, Lara Roberts, et al.
British Journal of Haematology|September 8, 2006
Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cellsVictoria L Grandage, Tamara Everington, David C Linch, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|April 20, 2004
-455G/A beta-fibrinogen gene polymorphism, factor V Leiden, prothrombin G20210A mutation and MTHFR C677T, and placental vascular complicationsRaymond S Camilleri, Donald Peebles, Carol Portmann, et al.
The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland|December 6, 2019
Mechanical prophylaxis, early mobilisation and risk stratification: as effective as drugs for low risk patients undergoing primary joint replacement. Results in 13,384 patientsSukhdeep K Gill, Andrea R Pearce, Tamara Everington, et al.
Blood|June 23, 2009
In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigmJonathan R Lambert, Tamara Everington, David C Linch, et al.
Pageof 3